Neuroscientists at the Sainsbury Wellcome Centre (SWC) at University College London have uncovered a neural mechanism in mice ...

Researchers at CU Anschutz are studying the effect of psychedelic mushrooms on patients with treatment-resistant depression.

A new publication from Opto-Electronic Advances; DOI 10.29026/oea.2025.240152, discusses how multi-photon bionic skin ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

New research reveals how CBD and THC interact with brain receptors, unlocking potential for safer cannabis-based treatments.

Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

Early dysfunction of the endothelial/blood-brain barrier (BBB) is involved in the pathogenesis of cerebral small vessel disease (SVD), which is a contributor to about 50% of dementias.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Researchers have identified how CBD interacts with cannabinoid receptors to mitigate the negative effects of THC, the psychoactive component of cannabis.

Naloxone is a fantastic tool in reducing opioid deaths, but gentler versions would be helpful for fighting overdose ...